X4 Pharmaceuticals Inc
XFOR3.929USD
-0.381-8.84%
Market hours （ET）Quotes delayed by 15 min
236.16KMarket Cap
LossP/E TTM
More Details of X4 Pharmaceuticals Inc Company
X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. It has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
X4 Pharmaceuticals Inc Info
Ticker SymbolXFOR
Company nameX4 Pharmaceuticals Inc
IPO dateNov 16, 2017
CEO- -
Number of employees143
Security typeOrdinary Share
Fiscal year-endNov 16
Address61 North Beacon Street
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02134
Phone18575298300
Websitehttps://www.x4pharma.com/
Ticker SymbolXFOR
IPO dateNov 16, 2017
CEO- -
Company Executives of X4 Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. John Volpone
Mr. John Volpone
President, Chief Operating Officer
President, Chief Operating Officer
289.88K
--
Mr. Michael S. Wyzga
Mr. Michael S. Wyzga
Lead Independent Director
Lead Independent Director
4.05K
-37.02%
Dr. Gary J. Bridger, Ph.D.
Dr. Gary J. Bridger, Ph.D.
Director
Director
3.22K
-46.55%
Dr. Murray W. Stewart, M.D.
Dr. Murray W. Stewart, M.D.
Director
Director
--
--
Mr. Daniel Ferry
Mr. Daniel Ferry
Managing Director
Managing Director
--
--
Ms. Francoise De Craecker
Ms. Francoise De Craecker
Independent Director
Independent Director
--
--
Dr. Adam Raymond Craig, M.D., Ph.D.
Dr. Adam Raymond Craig, M.D., Ph.D.
Executive Chairman of the Board, Principal Executive Officer
Executive Chairman of the Board, Principal Executive Officer
--
--
Mr. David H. Kirske
Mr. David H. Kirske
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. John Volpone
Mr. John Volpone
President, Chief Operating Officer
President, Chief Operating Officer
289.88K
--
Mr. Michael S. Wyzga
Mr. Michael S. Wyzga
Lead Independent Director
Lead Independent Director
4.05K
-37.02%
Dr. Gary J. Bridger, Ph.D.
Dr. Gary J. Bridger, Ph.D.
Director
Director
3.22K
-46.55%
Dr. Murray W. Stewart, M.D.
Dr. Murray W. Stewart, M.D.
Director
Director
--
--
Mr. Daniel Ferry
Mr. Daniel Ferry
Managing Director
Managing Director
--
--
Ms. Francoise De Craecker
Ms. Francoise De Craecker
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Feb 21
Updated: Sat, Feb 21
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Empery Asset Management, L.P.
9.85%
Fidelity Management & Research Company LLC
9.35%
Morgan Stanley Investment Management Inc. (US)
9.02%
Perceptive Advisors LLC
6.95%
Saturn V Capital Management LP
6.38%
Other
58.46%
Shareholders
Shareholders
Proportion
Empery Asset Management, L.P.
9.85%
Fidelity Management & Research Company LLC
9.35%
Morgan Stanley Investment Management Inc. (US)
9.02%
Perceptive Advisors LLC
6.95%
Saturn V Capital Management LP
6.38%
Other
58.46%
Shareholder Types
Shareholders
Proportion
Hedge Fund
26.71%
Investment Advisor
25.37%
Investment Advisor/Hedge Fund
24.09%
Private Equity
7.13%
Venture Capital
5.71%
Research Firm
1.16%
Individual Investor
0.74%
Pension Fund
0.12%
Other
8.98%
Institutional Shareholding
Updated: Wed, Jan 21
Updated: Wed, Jan 21
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q4
148
27.08M
9.67%
--
2025Q4
209
30.02M
34.33%
+20.55M
2025Q3
203
11.99M
31.56%
+7.22M
2025Q2
221
3.50M
59.08%
-1.79M
2025Q1
225
3.45M
58.17%
-2.00M
2024Q4
216
103.66M
60.78%
-53.08M
2024Q3
212
110.90M
65.83%
-43.36M
2024Q2
209
114.19M
68.28%
-40.11M
2024Q1
203
115.38M
69.15%
-30.64M
2023Q4
192
109.42M
65.98%
-32.86M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Empery Asset Management, L.P.
2.39M
2.73%
+2.39M
--
Sep 30, 2025
Perceptive Advisors LLC
5.91M
6.76%
+5.91M
--
Oct 27, 2025
Deep Track Capital LP
1.12M
1.28%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
410.49K
0.47%
+178.59K
+77.02%
Sep 30, 2025
New Enterprise Associates (NEA)
3.23M
3.7%
+1.00M
+44.77%
Oct 27, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Value ETF
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
Vanguard US Momentum Factor ETF
0%
iShares Micro-Cap ETF
0%
Global X Russell 2000 Covered Call ETF
0%
iShares Russell 3000 ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
View more
ProShares UltraPro Russell2000
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Vanguard US Momentum Factor ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
iShares Russell 3000 ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Apr 24, 2025
Merger
30→1
Date
Ex-dividend Date
Type
Ratio
Apr 24, 2025
Merger
30→1
